ATE171193T1 - Tumorantigen-spezifischer antikörper - Google Patents

Tumorantigen-spezifischer antikörper

Info

Publication number
ATE171193T1
ATE171193T1 AT92850166T AT92850166T ATE171193T1 AT E171193 T1 ATE171193 T1 AT E171193T1 AT 92850166 T AT92850166 T AT 92850166T AT 92850166 T AT92850166 T AT 92850166T AT E171193 T1 ATE171193 T1 AT E171193T1
Authority
AT
Austria
Prior art keywords
antibody
specific antibodies
tumor antigen
antigen
culturing
Prior art date
Application number
AT92850166T
Other languages
German (de)
English (en)
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE171193T1 publication Critical patent/ATE171193T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92850166T 1991-07-03 1992-07-03 Tumorantigen-spezifischer antikörper ATE171193T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
ATE171193T1 true ATE171193T1 (de) 1998-10-15

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92850166T ATE171193T1 (de) 1991-07-03 1992-07-03 Tumorantigen-spezifischer antikörper

Country Status (19)

Country Link
US (1) US5552293A (https=)
EP (1) EP0521842B1 (https=)
JP (1) JP3194020B2 (https=)
KR (1) KR100246681B1 (https=)
AT (1) ATE171193T1 (https=)
AU (2) AU658198B2 (https=)
CA (1) CA2073124C (https=)
DE (1) DE69226990T2 (https=)
DK (1) DK0521842T3 (https=)
EE (1) EE03031B1 (https=)
ES (1) ES2124250T3 (https=)
FI (1) FI109207B (https=)
HU (2) HU218084B (https=)
IE (1) IE80841B1 (https=)
IL (1) IL102390A (https=)
NO (1) NO315472B1 (https=)
NZ (1) NZ243435A (https=)
SE (1) SE9102074D0 (https=)
WO (2) WO1993001302A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ES2619313T3 (es) 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
WO2004004639A2 (en) * 2002-07-02 2004-01-15 Smithkline Beecham Corporation A novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL3524611T3 (pl) 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
BRPI1010620B8 (pt) 2009-06-03 2021-05-25 Immunogen Inc métodos de conjugação
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
SG11201806478PA (en) 2016-02-05 2018-08-30 Immunogen Inc Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
WO2019035034A1 (en) * 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
DK0610179T3 (da) * 1990-07-20 1997-03-24 Pharmacia & Upjohn Ab Målspecifikke antistof-superantigenkonjugater og fremstilling deraf

Also Published As

Publication number Publication date
US5552293A (en) 1996-09-03
IE922188A1 (en) 1993-01-13
WO1993001302A1 (en) 1993-01-21
JP3194020B2 (ja) 2001-07-30
IL102390A (en) 1996-01-19
DE69226990D1 (de) 1998-10-22
CA2073124A1 (en) 1993-01-04
EP0521842A2 (en) 1993-01-07
KR100246681B1 (ko) 2000-04-01
EE03031B1 (et) 1997-08-15
NO315472B1 (no) 2003-09-08
HU218084B (hu) 2000-05-28
NO934777L (no) 1994-02-11
DK0521842T3 (da) 1999-06-14
HUT71193A (en) 1995-11-28
NZ243435A (en) 1994-10-26
JPH05276987A (ja) 1993-10-26
FI935970A0 (fi) 1993-12-31
IL102390A0 (en) 1993-01-14
SE9102074D0 (sv) 1991-07-03
WO1993001303A1 (en) 1993-01-21
NO934777D0 (no) 1993-12-22
FI935970L (fi) 1993-12-31
EP0521842B1 (en) 1998-09-16
AU658198B2 (en) 1995-04-06
HU9400011D0 (en) 1994-05-30
IE80841B1 (en) 1999-03-24
DE69226990T2 (de) 1999-03-25
AU2292092A (en) 1993-02-11
CA2073124C (en) 2007-06-19
HU211512A9 (en) 1995-11-28
FI109207B (fi) 2002-06-14
AU1942592A (en) 1993-01-07
EP0521842A3 (https=) 1994-01-26
ES2124250T3 (es) 1999-02-01

Similar Documents

Publication Publication Date Title
ATE171193T1 (de) Tumorantigen-spezifischer antikörper
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
EP0822830A4 (en) HUMAN ANTIBODIES FROM IMMUNIZED XENOMAS
FI913891A7 (fi) Uusi monoklonaalinen vasta-aine uutta antigeenia vastaan, joka liittyy ihmisen kasvaimiin
EP0597829A4 (en) MONOCLONAL ANTIBODIES AGAINST A NEW ANTIQUE ASSOCIATED WITH HUMAN TUMORS.
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
EP0344134A3 (en) Monoclonal antibody specific to a fibronectin sequence expressed in transformed cells, hybridoma secreting said antibody and use of said monoclonal antibody in the diagnosis of tumors
DE3684211D1 (https=)
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
EP0218158A3 (en) Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ATE243742T1 (de) Hybridzelle und deren verwendung zur herstellung eines arzneimittels zur induktion einer tumorimmunität
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
EP0512023A4 (en) Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens
ATE136937T1 (de) Antikörper gegen hamsterimmunglobulinen
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee